Table 2:

Advantages and disadvantages of CAR T-cell therapy vs CAR NK-cell therapy(83, 84)

	CAR T-cell therapy	CAR NK-cell therapy
Data currently available	Clinical data	Preclinical data
In-vivo persistence	Better	Worse
CRS/Cytopenia	More likely	Less likely
Viral transduction efficiency	Higher	Lower
Allogeneic/off-the-shelf product	Risk of GVHD if allogeneic	No risk of GVHD
Tumour recognition	Solely dependent on CAR	Multiple mechanisms including native receptor and CAR
CAR antigen downregulation	More likely	Less likely